Journal of General Internal Medicine

, Volume 33, Issue 9, pp 1426–1428 | Cite as

The Form and Content of Cannabis Products in the United States

  • Stacey Steigerwald
  • Peggy O. Wong
  • Arianne Khorasani
  • Salomeh Keyhani
Concise Research Reports


Thirty states have legalized cannabis in some form. Cannabis potency is largely estimated from cannabis seized in drug raids and state-controlled producers. Little data exists about the tetrahydrocannabinol (THC) content and form of products commercially available.

Recreational states have defined potency thresholds in edibles, limiting THC to 50 or 100 mg per package and 5 or 10 mg per serving depending on the state. No clear limit exists on THC in other product forms. In addition, while recreational states prohibit false marketing claims and advertising aimed at children, no data exists on how well regulations are enforced.1

We collected data on form, THC concentration, and associated marketing claims of products in dispensaries to better understand products available and marketing targeted at the public.


We identified the top three dispensaries with the most consumer reviews as a metric of public interest, reviewing a total 65 dispensaries. Six states and DC do...


Compliance with Ethical Standards

Conflict of Interest

The authors whose names are listed in this publication certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership; employment consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    Hibpshman D. Marijuana licensing updates [PowerPoint Slides]. 2017. Retrieved from
  2. 2.
    Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195–212.CrossRefPubMedGoogle Scholar
  5. 5.
    Nugent SM, Morasco BJ, O’Neil ME, Freeman M, Low A, Kondo K, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167:319–31. doi: Scholar
  6. 6.
    Wang GS, et al. Unintentional pediatric exposures to Marijuana in Colorado, 2009-2015. JAMA Pediatr. 2016;170(9):e160971.CrossRefPubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine (This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply) 2018

Authors and Affiliations

  • Stacey Steigerwald
    • 1
  • Peggy O. Wong
    • 1
  • Arianne Khorasani
    • 2
  • Salomeh Keyhani
    • 3
    • 4
  1. 1.NCIRE, San Francisco VA Medical CenterSan FranciscoUSA
  2. 2.John Abbot CollegeMontrealCanada
  3. 3.Department of MedicineUniversity of California at San FranciscoSan FranciscoUSA
  4. 4.San Francisco VASan FranciscoUSA

Personalised recommendations